Please login to the form below
IQWiG
This page shows the latest IQWiG news and features for those working in and with pharma, biotech and healthcare.
Blind man's buff
In IQWIG’s words, ‘the rhetoric of novelty and innovation creates an assumption that new products are better than existing ones’. ... The IQWIG evidence tells us that our industry is wasteful of its innovative resources.
Latest news
-
Diurnal files adrenal insufficiency drug Alkindi in US
Care (IQWiG) concluded it had not been proven to be superior to generic hydrocortisone.
-
Resurgent Diurnal raises £5.4m for twin product filings
IQWiG) concluded it had not been proven to be superior to generic hydrocortisone.
-
Transforming access in rare diseases
From IQWiG in Germany to the HAS in France and the Pharmaceutical Benefits Advisory Committee in Australia, the reality we face is that all technology assessment organisations work in slightly different
-
Focus on value: A prescription for pharma
The pricing debate demands a common language to be developed
-
NICE backs use of AZ's Brilique as maintenance therapy
A similar verdict was reached by NICE's German counterpart IQWiG earlier this year.
Diurnal files adrenal insufficiency drug Alkindi in US
Transforming access in rare diseases
Focus on value: A prescription for pharma
NICE backs use of AZ's Brilique as maintenance therapy
More from news
Approximately 23 fully matching, plus 45 partially matching documents found.
Latest Intelligence
-
Market shaping demands behaviour change
In fact, a 2019 study conducted by the German HTA organisation IQWiG concluded that they deem two-thirds of new innovations reaching the market today offer limited or no additional value
-
The gold standard of scientific evidence
PBAC appraisals, 64% of NICE appraisals and all IQWiG appraisals relied on RCT-based evidence.
-
Digital disruption
best patient outcomes - information that would probably come in very handy for submissions to the likes of NICE or IQWiG.
-
Stepping up to payer-driven market access
Combined with the demanding - and often less familiar - requirements of the GBA and IQWIG in Germany and other agencies in Europe, these changes make early understanding of the payer environment critical
-
The price is right?
IQWiG evaluations often focus on different patient populations from those used in the clinical trials. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely complex process.”.
Market shaping demands behaviour change
The gold standard of scientific evidence
Digital disruption
Stepping up to payer-driven market access
The price is right?
More from intelligence
Approximately 4 fully matching, plus 18 partially matching documents found.
Latest from PMHub
-
Oncology drugs under AMNOG
Usually the G-BA also seeks the advice of expert Health Technology Assessment (HTA) body IQWiG (the Institute for Quality and Efficiency in Healthcare), to determine the level of added benefit ... The G-BA and IQWiG restricted these options to therapies
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Unlocking the Potential of Electronic Medical Records Using Artificial Intelligence
- Valneva COVID-19 vaccine more effective than AZ
- Real-world data highlights flu vaccine efficacy
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Best practice in UK diabetes care recognised at prestigious national awards
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Beyond yoga and smoothies – providing real support for employee well-being
- The Future of eHealth: Contactless Health Monitoring
- How do you define a biotech company?
- Attracting the best talent to build Lucid’s future
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
